ScreenerHero

MNOV MediciNova, Inc.

NAS · US · Healthcare · Biotechnology · medicinova.com
1.610USD-2.42%Mkt Cap: 79.25M $P/E: —

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilas…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap79.25M USD
Enterprise Value55.92M USD
Revenue (TTM)920.48K USD
Gross Profit31.05K USD
Net Income (TTM)-12.00M USD
Revenue/Share0.02 USD
Last Price1.610 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees6
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.20
PEG—
EV/EBITDA-4.73
EV/Revenue60.75
P/S88.23
P/B2.18
EPS (TTM)-0.21
EPS (Forward)-0.52
52W Range
1.17018% of range3.611
52W High3.611 USD
52W Low1.170 USD
Profitability
Gross Margin7.58%
Oper. Margin-554.31%
EBITDA Margin0.00%
Profit Margin-2928.78%
ROE-28.85%
ROA-26.31%
Growth
Revenue Growth240.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.81M USD
CapEx (TTM)2.90K USD
FCF Margin-623.47%
FCF Yield-7.24%
Net Debt-25.30M USD
Net Debt/EBITDA2.14
Balance Sheet
Debt/Equity0.00
Current Ratio8.75
Quick Ratio8.58
Book Value/Sh0.76 USD
Cash/Share0.52 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.250 USD
Upside (mean)+412.4%
Target Range6.000 USD – 11.00 USD
6.000+412.4% to mean11.00
# Analysts4
Ownership
Shares Out.49.22M
Float42.94M
Insiders2.86%
Institutions20.38%
Short Interest
Short Ratio5.6d
Short % Float0.78%
Short % Out.0.76%
Shares Short374.67K
Short (prev mo.)331.44K
Technical
SMA 501.747 (-7.9%)
SMA 2001.508 (+6.8%)
Beta0.61
S&P 52W Chg16.45%
Avg Vol (30d)393.21K
Avg Vol (10d)455.35K
Technical Indicators
RSI (14)41.5
MACD-0.0098
MACD Signal0.1184
MACD Hist.-0.1282
BB Upper3.308 USD
BB Middle2.158 USD
BB Lower1.007 USD
BB Width106.63%
ATR (14)0.2275 USD
Vol Ratio (20d)0.14x